MoonLake Immunotherapeutics宣布,美国食品药品监督管理局已接受其Mira试验及Vela-Teen试验的数据,这些数据将用于支持其候选药物Sonelkimab的生物制品许可申请提交。
MoonLake Immunotherapeutics宣布,美国食品药品监督管理局已接受其Mira试验及Vela-Teen试验的数据,这些数据将用于支持其候选药物Sonelkimab的生物制品许可申请提交。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.